文献速递认知障碍与痴呆

二甲双胍与磺脲类对老年2型糖尿病退伍军人痴呆风险的影响

Metformin vs sulfonylurea use and risk of dementia in US veterans aged ≥65 years with diabetes.
PubMed 文献 · Neurology · 2017-09-27

本研究为回顾性队列研究,纳入17,200名新使用二甲双胍和11,440名新使用磺脲类的≥65岁美国2型糖尿病退伍军人,随访平均5年。经倾向评分逆概率加权调整后,<75岁者二甲双胍与较低痴呆风险相关(HR 0.89, 95%CI 0.79-0.99),≥75岁者无显著差异(HR 0.96, 95%CI 0.87-1.05)。

要点

  • 在<75岁退伍军人中,二甲双胍与较低的痴呆风险相关。
  • ≥75岁退伍军人中,二甲双胍与磺脲类的痴呆风险无显著差异。
  • <75岁且HbA1c≥7%或肾功能良好者,二甲双胍的痴呆风险更低。

核心结论

  • 经倾向评分逆概率加权调整后,<75岁退伍军人中二甲双胍与较低的痴呆风险相关,≥75岁者无显著差异。

研究设计与样本

  • 回顾性队列研究,纳入17,200名新使用二甲双胍和11,440名新使用磺脲类的≥65岁美国2型糖尿病退伍军人,随访平均5年。

主要发现

  • 平均年龄73.5岁,平均HbA1c 6.8%,随访期间诊断4,906例痴呆。
  • 粗HR:<75岁为0.67(95%CI 0.61-0.73),≥75岁为0.78(95%CI 0.72-0.83)。
  • 经PS IPTW调整后,<75岁HR为0.89(95%CI 0.79-0.99),≥75岁HR为0.96(95%CI 0.87-1.05)。
  • <75岁且HbA1c≥7%者HR为0.76(95%CI 0.63-0.91),肾功能良好者HR为0.86(95%CI 0.76-0.97),白人HR为0.87(95%CI 0.77-0.99)。

临床怎么用

  • 对于<75岁的2型糖尿病退伍军人,二甲双胍可能较磺脲类降低痴呆风险。
  • 需进一步研究确定哪些患者可能从二甲双胍的痴呆预防中获益。

局限性

  • 回顾性队列设计可能存在残余混杂。
  • 研究人群为美国退伍军人,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether metformin is associated with a lower incidence of dementia than sulfonylureas. METHODS: This was a retrospective cohort study of US veterans ≥65 years of age with type 2 diabetes who were new users of metformin or a sulfonylurea and had no dementia. Follow-up began after 2 years of therapy. To account for confounding by indication, we developed a propensity score (PS) and used inverse probability of treatment weighting (IPTW) methods. Cox proportional hazards models estimated the hazard ratio (HR) of incident dementia. RESULTS: We identified 17,200 new users of metformin and 11,440 new users of sulfonylureas. Mean age was 73.5 years and mean HbA1c was 6.8%. Over an average follow-up of 5 years, 4,906 cases of dementia were diagnosed. Due to effect modification by age, all analyses were conducted using a piecewise model for age. Crude hazard ratio [HR] for any dementia in metformin vs sulfonylurea users was 0.67 (95% confidence interval [CI] 0.61-0.73) and 0.78 (95% CI 0.72-0.83) for those <75 years of age and ≥75 years of age, respectively. After PS IPTW adjustment, results remained significant in veterans <75 years of age (HR 0.89; 95% CI 0.79-0.99), but not for those ≥75 years of age (HR 0.96; 95% CI 0.87-1.05). A lower risk of dementia was also seen in the subset of younger veterans who had HbA1C values ≥7% (HR 0.76; 95% CI 0.63-0.91), had good renal function (HR 0.86; 95% CI 0.76-0.97), and were white (HR 0.87; 95% CI 0.77-0.99). CONCLUSIONS: After accounting for confounding by indication, metformin was associated with a lower risk of subsequent dementia than sulfonylurea use in veterans <75 years of age. Further work is needed to identify which patients may benefit from metformin for the prevention of dementia.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Orkaby AR, Cho K, Cormack J, et al. Metformin vs sulfonylurea use and risk of dementia in US veterans aged ≥65 years with diabetes. Neurology. 2017. PMID: 28954880. doi:10.1212/WNL.0000000000004586

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。